These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35554651)

  • 21. Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on
    Chiang MT; Wang JT; Lin WY; Yen RF; Huang JY; Lu CC
    Eur J Med Res; 2023 Nov; 28(1):513. PubMed ID: 37964395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines.
    Adin ME; Isufi E; Wu J; Pang Y; Nguyen D; Simsek Has D; Caner C; Aboueldaha N; Mossa-Basha M; Pucar D
    Nucl Med Commun; 2024 Jun; 45(6):474-480. PubMed ID: 38465449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axillary Lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 Vaccination: MRI Evaluation.
    Yoshikawa T; Miki S; Nakao T; Koshino S; Hayashi N; Abe O
    Radiology; 2023 Jan; 306(1):270-278. PubMed ID: 36098641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of COVID-19 Vaccination.
    Edmonds CE; Zuckerman SP; Conant EF
    AJR Am J Roentgenol; 2021 Oct; 217(4):831-834. PubMed ID: 33543649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 vaccine-induced lymphadenopathies: incidence, course and imaging features from an ultrasound prospective study.
    Romeo V; Stanzione A; D'Auria D; Fulgione L; Giusto F; Maurea S; Brunetti A
    J Ultrasound; 2022 Dec; 25(4):965-971. PubMed ID: 35507248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [
    Cohen D; Krauthammer SH; Wolf I; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1854-1863. PubMed ID: 33774684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications.
    Sahoo SS; Kaur N; Kaur A; Garg S
    Ther Adv Vaccines Immunother; 2022; 10():25151355221124018. PubMed ID: 36133302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.
    Mema E; Lane EG; Drotman MB; Eisen CS; Thomas C; Prince MR; Dodelzon K
    AJR Am J Roentgenol; 2023 Aug; 221(2):175-183. PubMed ID: 36883774
    [No Abstract]   [Full Text] [Related]  

  • 31. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients.
    Özütemiz C; Krystosek LA; Church AL; Chauhan A; Ellermann JM; Domingo-Musibay E; Steinberger D
    Radiology; 2021 Jul; 300(1):E296-E300. PubMed ID: 33625300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound Features to Differentiate COVID-19 Vaccine-Induced Benign Adenopathy from Breast Cancer Related Malignant Adenopathy.
    Hl C; Gj W; Jwt L; J S; Lp M; Ht LP
    Acad Radiol; 2022 Jul; 29(7):1004-1012. PubMed ID: 35296413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
    BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy.
    Park JS; Minn D; Hong S; Jeong S; Kim S; Lee CH; Kim B
    J Korean Med Sci; 2022 Jun; 37(23):e180. PubMed ID: 35698835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unilateral Axillary Lymphadenopathy after the Inactivated SARS-COV-2 (CoronaVac) Vaccine: Ultrasonographic Imaging.
    Elverici E; Özsoy A; Sayın B; Gökhan MB; Özkan E
    Balkan Med J; 2023 Jan; 40(1):28-33. PubMed ID: 36421031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics.
    Nishino M; Hatabu H; Ricciuti B; Vaz V; Michael K; Awad MM
    J Thorac Oncol; 2022 Jan; 17(1):154-159. PubMed ID: 34506955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.